Latest Study: Cholera Vaccine Market is expanding at $207 Million by 2025 with growing CAGR | Hospitals & Clinics Segment is fastest growth rates

The global cholera vaccine market was valued $65 Million in 2017, and is projected to reach $207 Million by 2025, with a growing CAGR of 15.6% during forecast period 2018 to 2025.

A vaccine is a biological preparation that assists in strengthening the immune system and provides acquired immunity against a specific pathogen. Vaccinations have proved to be one of the best methods to treat infectious diseases by many international organizations such as the World Health Organization (WHO). Cholera is one of the type of infectious disease caused by the bacterium Vibrio cholera. It is associated with the severe diarrhea and the immediate treatment is essential as death is inevitable if the disease is left untreated.

Cholera is anticipated to be a global threat to public health especially in regions that lack social development. Thus, cholera vaccine is essential to control cholera. There are two types of cholera vaccine available in the market including inactivated and live oral cholera vaccines, whereas inactivated cholera vaccines are successfully employed globally. These vaccines are mainly taken by travelers and the people who are living in the cholera affected region. In addition, WHO is recommended that cholera vaccine should be taken at least 2 weeks before arrival at the destination and at least 1 week of gap between the doses. Hence, these aforementioned factors helps in increasing the global cholera vaccine market share.

Download Sample Report @ https://www.alliedmarketresearch.com/request-sample/5177?utm_source=opr_sank

Key Findings Of The Global Cholera Vaccine Market Study:

• Based on product, the Vaxchora segment is expected to experience rapid growth in the market, and is projected to grow at a CAGR of 17.4% from 2018 to 2025.
• Depending on end user, the pharmaceutical & biotechnology companies segment is expected to exhibit the highest CAGR during the forecast period.
• U.S. generated the highest revenue in the global cholera vaccine market industry in 2017, accounting less than one-tenth of the global market in 2017.
• North America is estimated to grow at a CAGR of 17.1% during the forecast period.

The Dukoral segment accounted around half of the total market share in 2017.

The cholera vaccine market is expected to exhibit significant growth during the forecast period due to lack of proper sanitation & consumption of contaminated food and growth in awareness about cholera preventive care. In addition, development of novel approaches for new cholera vaccine further drive the market growth. However, risk of adverse effects and the time taken for the regulatory approval is projected to impede the market growth. On the contrary, high growth opportunities in untapped markets are expected to offer significant profitable opportunities for the market players in the near future.

Based on end user, the market is categorized into hospitals & clinics, research & academic laboratories, and others. The hospitals & clinics segment presently dominates the market, and is expected to remain dominant during the forecast period. This is attributed to the fact that hospitals and clinics are authorized to organize campaigns for cholera vaccination, as the number of cases for cholera diseases is rapidly growing in LMICs.

Asia-Pacific was the leading revenue contributor to the global cholera vaccine market in 2017, and is expected to remain dominant throughout the forecast period due to increase in the prevalence of cholera disease and rise in importance of immunization. However, North America is expected to grow at the highest CAGR during the study period. This is attributed to the launch of the first and only oral cholera vaccine, Vaxchora, in the USA. Furthermore, the number of travelers to the cholera-affected countries is increasing, which in turn increases the demand for immunization.

The report provides a comprehensive analysis of the key players operating in the global cholera vaccine market industry, namely Valneva SE, Emergent BioSolutions, Inc. (PaxVax, Inc.), Astellas Pharma, Inc., Sanofi (Shantha Biotechnics Private Limited), Eubiologics Co., Ltd., and Johnson & Johnson (Crucell), Celldex Therapeutics, Inc. The other players in the in the cholera vaccine market industry include Merck & Co., Inc., GlaxoSmithKline plc., and others.

Flat 20% Discount on All License Type.. https://www.alliedmarketresearch.com/checkout/309046
*Offer Valid Till 20th April 2019

About us

Allied Market Research, a market research and advisory company of Allied Analytics LLP, provides business insights and market research reports to large as well as small & medium enterprises. The company assists its clients to strategize business policies and achieve sustainable growth in their respective market domain.

Allied Market Research provides one stop solution from the beginning of data collection to investment advice. The analysts at Allied Market Research dig out factors that help clients to understand the significance and impact of market dynamics. The company amplies client's insight on the factors, such as strategies, future estimations, growth or fall forecasting, opportunity analysis, and consumer surveys among others. As follows, the company offers consistent business intelligent support to aid the clients to turn into prominent business firm.

Contact:

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free: +1-800-792-5285
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com
Web: www.alliedmarketresearch.com

This release was published on openPR.